Table 2.
Study design and results of SUSTAIN trials
| SUSTAIN | Clinical trial identification number | Population | Duration (weeks) |
Background medication | Semaglutide trial dose & Comparator | % HbA1c reduction | Weight loss (kg) |
|---|---|---|---|---|---|---|---|
| 1 | NCT02054897 | 388 | 30 | None | 0.5 mg | -1.45 | -3.73 |
| 1.0 mg | -1.55 | -4.53 | |||||
| Placebo | -0.02 | -0.98 | |||||
| 2 | NCT01930188 | 1231 | 56 | Metformin and/or Pioglitazone/Rosiglitazone | 0.5 mg | -1.3 | -4.3 |
| 1.0 mg | -1.6 | -6.1 | |||||
| Sitagliptin (100 mg) | -0.5 | -1.9 | |||||
| 3 | NCT01885208 | 813 | 56 | Metformin and/or Thiazolidinediones and/or Sulfonylurea | 1.0 mg | -1.5 | -5.6 |
| Exenatide ER (2.0 mg) | -0.9 | -1.9 | |||||
| 4 | NCT02128932 | 1089 | 30 | Metformin alone or with Sulfonylurea | 0.5 mg | -1.21 | -3.74 |
| 1.0 mg | -1.64 | -5.71 | |||||
| Insulin glargine | -0.83 | +1.15 | |||||
| 5 | NCT02305381 | 397 | 30 | Basal insulin alone or with Metformin | 0.5 mg | -1.4 | -3.7 |
| 1.0 mg | -1.8 | -6.4 | |||||
| Placebo | -0.1 | -1.4 | |||||
| 6 | NCT01720446 | 3297 (83% with CV and/or CKD) | 104 | None | 0.5 mg | -1.1 | -3.6 |
| 1.0 mg | -1.4 | -4.9 | |||||
| Placebo (0.5 mg) | -0.4 | -0.7 | |||||
| Placebo (1.0 mg) | -0.4 | -0.5 | |||||
| 7 | NCT02648204 | 1201 | 40 | Metformin | 0.5 mg | -1.5 | -4.6 |
| 1.0 mg | -1.8 | -6.5 | |||||
| Dulaglutide (0.75 mg) | -1.1 | -2.3 | |||||
| Dulaglutide (1.5 mg) | -1.4 | -3.0 | |||||
| 8 | NCT03136484 | 788 | 52 | Metformin | 1.0 mg | -1.5 | -5.3 |
| Canagliflozin (300 mg) | -1.0 | -4.2 | |||||
| 9 | NCT03086330 | 302 | 30 | SGLT-2 inhibitor alone or with Sulfonylurea/Metformin | 1.0 mg | -1.5 | -4.7 |
| Placebo | -0.1 | -0.9 | |||||
| 10 | NCT03191396 | 577 | 30 | Metformin and Sulfonylurea/SGLT-2 inhibitor | 1.0 mg | -1.7 | -5.8 |
| Liraglutide (1.2 mg) | -1.0 | -1.9 | |||||
| 11 | NCT03689374 | 2275 | 52 | Metformin alone or with Sulfonylurea/Meglitinide/DPP-4 inhibitor/α-glucosidase inhibitor | 1.0 mg | - | - |
| Insulin aspart (4 IU) | - | - | |||||
| Japan-sitagliptin | NCT02254291 | 308 | 30 | None | 0.5 mg | -1.9 | -2.2 |
| 1.0 mg | -2.2 | -3.9 | |||||
| Sitagliptin (100 mg) | -0.7 | 0.0 | |||||
| Japan | NCT02207374 | 601 | 56 | None | 0.5 mg | -1.7 | -1.4 |
| 1.0 mg | -2.0 | -3.2 | |||||
| OAD monotherapy | -0.7 | +0.4 | |||||
| China-MRCT | NCT03061214 | 868 | 30 | Metformin | 0.5 mg | -1.4 | -2.9 |
| 1.0 mg | -1.7 | -4.2 | |||||
| Sitagliptin (100 mg) | -0.9 | -0.4 | |||||
| FORTE | NCT03989232 | 961 | 40 | Metformin alone or with Sulfonylurea | Trial product estimand | Treatment policy estimand | |
| 1.0 mg | -1.9%, 6.0 kg | -1.9%, 5.6 kg | |||||
| 2.0 mg | -2.2%, 6.9 kg | -2.1%, 6.4 kg | |||||
| Placebo | - | - |